TNF Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on developing two novel therapeutic platforms that treat the causes of disease rather than addressing the symptoms. MYMD-1 is a drug platform based on a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. MYMD-1 is being developed to treat diseases and disorders marked by acute and chronic inflammation. The company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction, epilepsy, and anxiety/depression. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and aims to improve the growing CBD market, which includes FDA-approved drugs and CBD products not regulated as drugs. TNF Pharmaceuticals, Inc. was formerly known as MyMD Pharmaceuticals, Inc. and changed its name to TNF Pharmaceuticals, Inc. in July 2024. The company was founded in 2014 and is headquartered in New York, New York.